Talphera, Inc. (NASDAQ:TLPH) Short Interest Update

Talphera, Inc. (NASDAQ:TLPH) was the target of a significant decline in short interest in the month of June. As of June 15th, there was short interest totalling 139,800 shares, a decline of 16.9% from the May 31st total of 168,300 shares. Based on an average daily volume of 69,900 shares, the short-interest ratio is currently 2.0 days. Approximately 0.8% of the shares of the company are sold short.

Analyst Ratings Changes

Several equities analysts have weighed in on TLPH shares. Maxim Group assumed coverage on shares of Talphera in a report on Monday, May 6th. They set a “buy” rating and a $3.00 price target on the stock. HC Wainwright restated a “buy” rating and set a $6.00 target price on shares of Talphera in a research note on Wednesday, May 15th.

Talphera Stock Down 2.2 %

TLPH stock opened at $0.89 on Monday. Talphera has a 1-year low of $0.43 and a 1-year high of $1.61. The company has a 50-day moving average price of $1.00.

Talphera (NASDAQ:TLPH) last issued its quarterly earnings data on Tuesday, May 14th. The company reported ($0.16) EPS for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.12. On average, sell-side analysts anticipate that Talphera will post -0.84 EPS for the current fiscal year.

Talphera Company Profile

Talphera, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit.